Evidence map›Paper›PMID 31801570›Full record

ArticleOrphanet journal of rare diseases2019

Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.

Marlene Guiraud, Athmane Bouroubi, Roxane Beauchamp, Arnaud Bocquet, Jean-Marc Grégoire, Isabelle Rauly-Lestienne, Ignacio Blanco, Pierre Wolkenstein, Anne-Marie Schmitt

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Marlene GuiraudInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France. marlene.guiraud@pierre-fabre.com.
Athmane BouroubiInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France.
Roxane BeauchampInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France.
Arnaud BocquetInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France.
Jean-Marc GrégoireInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France.
Isabelle Rauly-LestienneInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France.
Ignacio BlancoGenetic Counseling and Clinical Genetics Program, Laboratori Clínic Metropolitana Nord, Hospital Germans Tias, 08916, Badalona, Spain.
Pierre WolkensteinCHU Henri Mondor, 94010, Créteil, France.
Anne-Marie SchmittInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation Unit, 3 avenue Hubert Curien - BP 13562 31035, Toulouse Cedex 1, France.
Pierre Fabre (France) · FRCentre Hospitalier Universitaire Henri-Mondor · FRHospital Universitari Germans Trias i Pujol · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to perceive their satisfaction and feelings about cNF current management (only laser and surgery are currently available), and to highlight their expectations of new therapeutic modalities.

resultsOne hundred seventy patients from 4 European countries took part in the study, 65% (n = 110) were women and mean age was 39 years old. 96% (n = 164) of respondents have cNF on visible parts of the body and the survey confirmed that total number of cNF and visibility increase with age. Patients reported that cNF mainly impacts everyday mood, general daily life and social life. The visibility of cNF had a higher impact than their number. 92% (n = 156) of patients have a regular and multidisciplinary medical follow-up. The dermatologist is one of the most consulted healthcare professionals. 76% (n = 130) of respondents have treated their cNF: 65% (n = 111) had surgery and 38% (n = 64) had multiple laser sessions. Frequency of operations and regrowth of cNF were the two most unsatisfactory aspects with both treatments for patients. Indeed, after removal, new cNF appear in more than 75% (n = 128) of cases. As a future treatment, patients expected a topical (30%, n = 51) or oral medication (29%, n = 50). Around 2 out of 3 patients would agree to take it at least once a day or more for life but they would like a well-tolerated treatment. According to patients, the most important effectiveness criteria of a new treatment are to block cNF growth and reduce their number. 70% (n = 119) of patients would consider a future treatment moderately effective to very effective if it could clear 30% of cNF.

conclusionsThis first cNF European patient community survey confirmed that the visible stigma and unaesthetic aspect of cNF have an important impact on patients' quality of life. The survey highlighted that patients were not entirely satisfied with the actual surgery and laser treatments and revealed their clear and realistic expectations for future treatment of cNF.

Indexed as

AdolescentAdultAgedEuropean UnionFemaleHumansMaleMiddle AgedMotivationNeurofibromaNeurofibromatosis 1Quality of LifeSkin NeoplasmsSurveys and QuestionnairesYoung AdultCutaneous neurofibromasFuture medicationNeurofibromatosis type 1Patient community surveyQuality of lifeReal-world experience

Identifiers

PMID31801570
PMCPMC6894276
OpenAlexW2992992513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.